Currently out of the existing stock ratings of Jason Butler, 225 are a BUY (92.98%), 15 are a HOLD (6.2%), 2 are a SELL (0.83%).

Jason Butler

Work Performance Price Targets & Ratings Chart

Analyst Jason Butler, carries an average stock price target met ratio of 37.32% that have a potential upside of 53.52% achieved within 214 days. Previously, Jason Butler worked at JMP.

Jason Butler’s has documented 493 price targets and ratings displayed on 43 stocks. The coverage was on Healthcare, Industrials sectors.

Most recent stock forecast was given on CYTK, Cytokinetics at 22-Dec-2025.

Wall Street Analyst Jason Butler

Analyst best performing recommendations are on TRVN (TREVENA).
The best stock recommendation documented was for HALO (HALOZYME THERAPEUTICS) at 2/24/2021. The price target of $48 was fulfilled within 1 day with a profit of $3.45 (6.71%) receiving and performance score of 67.06.

Average potential price target upside

of $80.62 (53.07%) on KRTX (KARUNA THERAPEUTICS).
of $50.2 (76.64%) on LRMR (LARIMAR THERAPEUTICS).
of $50.2 (76.64%) on ZFGN (ZAFGEN).

ACAD ACADIA Pharmaceuticals ADMS Adamas Pharmaceuticals ARGX argenx NV ADR ARNA Arena Pharmaceuticals AXGT Sio Gene Therapies CRMD CorMedix CYTK Cytokinetics ESPR Esperion Therapeutics HALO Halozyme Therapeutics ITCI Intracellular Th KRTX Karuna Therapeutics NEOS Neos Therapeutics NERV Minerva Neurosciences RZLT Rezolute SYRS Syros Pharmaceuticals VNDA Vanda Pharmaceuticals XON Precigen ZFGN Zafgen MYOV Myovant Sciences Ltd PLXP PLx Pharma AMTI Applied Molecular Transport AQST Aquestive Therapeutics ATHA Athira Pharma AXON Axon Enterprise CRTX Cortexyme ENTA Enanta Pharmaceuticals HOOK Hookipa Pharma LRMR Larimar Therapeutics PGEN Precigen GMDA Gamida Cell Ltd MRNS Marinus Pharmaceuticals CNCE Concert Pharmaceuticals MOR MorphoSys AG ADR OVID Ovid Therapeutics PRTO Proteon Therapeutics QNRX Quoin Pharmaceuticals Ltd DRC TRVN Trevena VRDN Viridian Therapeutics ZGNX Zogenix GHRS GH Research PLC PRTA Prothena plc TARA Protara Therapeutics VIGL Vigil Neuroscience

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jay Olson (OPPENHEIMER)